Lung Cancer Clinical Trial
Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
Summary
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
Full Description
The objective of this study is to determine the ability of cell free tumor DNA genomic profiling to predict disease relapse or progression while on therapy for advanced stage NSCLC in comparison to current standard objective measures of disease relapse or progression.
This study is a prospective observational study. The investigators will assess whole genome sequencing from patient blood samples collected alongside routine blood draws with each treatment cycle to determine the tumor load score at each timepoint while on therapy. CT images will be obtained at routinely ordered timepoints throughout therapy and will be used in the assessment for standard clinical or radiographic evidence of disease progression. These methods of measuring disease progression will be compared in a lead time analysis.
Eligibility Criteria
Inclusion Criteria:
Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC
Baseline CT imaging available
Exclusion Criteria:
Patients unable to undergo biopsy for initial tissue diagnosis
Patients who do not wish to pursue standard of care therapy
Patients with another diagnosis of malignancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Diego California, 92103, United States More Info
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.